ESMO Media Releases

KEYNOTE-010 data further supports broadening pembrolizumab availability for all advanced NSCLC patients with PD-L1 expression over 1%

LUX-Lung 7 trial reveals that the second-generation EGFR tyrosine kinase inhibitor significantly improved PFS in naive patients with advanced mutated lung cancer compared to gefitinib

Promising results of PALOMA3 trial confirmed in Asian patients

Phase I trial reports that pembrolizumab is active in nasopharyngeal cancer.  Afatinib is effective as second-line treatment in squamous cell carcinoma of the head and neck in a Phase II study

Underprivileged patients are at major risk of disease-related “financial catastrophe", study in eight low- and middle-income Southeast Asian countries shows

LUGANO/SINGAPORE, 16 December 2015 – ESMO, the leading professional organisation for medical oncology, is pleased to announce the inaugural ESMO Asia 2015 Congress in Singapore. A premier scientific and educational platform for oncologists and other stakeholders in cancer care, the Asian edition of ESMO’s annual congress aims to facilitate information exchange between researchers, clinicians and patients across disciplines to find the most effective treatment solutions.

CheckMate 017 clearly showed that the checkpoint inhibitor improves the overall health status in patients with advanced squamous non-small-cell lung cancer

Two drugs are changing the current landscape for the treatment of advanced renal cell carcinoma

Cancer is distressing for patients and families, and supportive care is today an important part of therapy

Gastric cancer (GC) is one of the most aggressive oncologic diseases, with a 5 year median survival of 25%. Surgery remains the only curative option, although with a high recurrence rate.

Novel approaches and drugs are showing promising results in solid cancers.

A small study presented at ECC2015 shows positive responses in patients with Merkel cell carcinoma after few weeks of treatment with checkpoint inhibitors